Cell-Free DNA Blood Test for Colorectal Cancer Screening: Benefits, Risks, and Cost-Effectiveness
Regular screening for colorectal cancer (CRC) is crucial for reducing incidence and mortality, according to guidelines from the US Preventive Services Task Force. While screening starts at age 45, many individuals remain behind on recommended screenings. New screening methods, including cell-free DNA blood tests (cf-bDNA), aim to improve access to testing.
How cf-bDNA Works
Approved by the FDA in July 2024, cf-bDNA tests analyze blood for fragments of DNA shed by tumors. These tests demonstrate high sensitivity for detecting advanced-stage CRC (stages II-IV). However, there are concerns about its potential shortcomings compared to established methods like colonoscopy and fecal immunochemical tests (FIT).
Exploring the Impact of cf-bDNA
A new study published in
Annals of Internal Medicine
1 aimed to evaluate the potential impact and cost-effectiveness of cf-bDNA compared to other CRC screening methods. Researchers used the Model of Screening and Surveillance for Colorectal Cancer (MOSAIC) to simulate screening scenarios with colonoscopy, FIT, a multitarget stool DNA (MT-sDNA) test, FIT-RNA, and cf-bDNA.
Although the new blood test is better than no screening, FIT and colonoscopies may remain the standard for screening for CRC | Image credit: angellodeco – stock.adobe.com
Key Findings
- Despite being superior to no screening, cf-bDNA demonstrated lower effectiveness and higher costs compared to colonoscopies and FIT.
- cf-bDNA’s relatively lower sensitivity for early-stage CRC (stage I) requires further investigation.
- The study highlights cf-bDNA’s potential to increase screening rates among individuals who might otherwise not undergo traditional methods.
Balancing Benefits and Risks
While the cf-bDNA test represents a potential advancement in CRC screening, it’s crucial to consider its limitations. Individuals already screening with FIT or colonoscopy may not necessarily benefit from switching to cf-bDNA. More research is needed to fully understand its long-term effectiveness and cost-effectiveness.
Conclusion
The cf-bDNA blood test shows promise in expanding CRC screening access, but its current efficacy and cost-effectiveness remain less favorable compared to established methods. Consulting with your healthcare provider is crucial to determine the most appropriate screening approach for your individual needs.
Beyond Screening: Take Control of Your Colorectal Health Today! Schedule a consultation with your doctor to discuss the best screening options for you.
Ann Intern Med
1. Published online October 29, 2024.
doi:10.7326/ANNALS-24-00910.